

NOV 13 '90 05:43PM NYBC

P.1

New York Blood Center

310 E. 67th Street, New York, NY 10021
212/570-3000 Fax 212/570-3195

CAD 17c1
~~0008~~ RM
14 OCT 90
0009

TELEFAX TRANSMISSION
#011 4431 229 1069

PAGE 1 OF 4

PLEASE HAND DELIVER TO DR. C.V. PROWSE

November 13, 1990

Dr. C.V. Prowse
Edinburgh & South East Scotland
Blood Transfusion Service
Department of Transfusion Medicine
Royal Infirmary of Edinburgh
Lauriston Place
Edinburgh EH3 9HB, Scotland

Dear Dr. Prowse:

Thank you for your telefax of November 12. We are happy to hear that the Scottish Blood Transfusion Service is reconsidering the use of the solvent/detergent technology for its products. The disclosure and license fees remain as quoted in 1989 (\$10,000 and \$15,000) as does the royalty (4%).

We are not aware of virus kill studies done on the viruses you mentioned. However, we would be interested in knowing the results of studies you may have done. A table which shows our experience with TNBP/detergent combinations on the inactivation of viruses is enclosed, as is a table which summarizes the results of the clinical trials using S/D-treated products.

I am told that for HIV we also dilute 200-fold, as you mentioned, or sometimes precipitate the HIV with PEG. I can contact Dr. Alfred Prince's lab at the NYBC, if you are interested in more information about this method.

Cordially yours,

GRO-C

Christine Watklevicz
Licensee Affairs